Ubs Group Ag Macrogenics Inc Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Macrogenics Inc stock. As of the latest transaction made, Ubs Group Ag holds 43,642 shares of MGNX stock, worth $75,937. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,642

Previous 37,684 15.81%

Holding current value

$75,937

Previous $47,000 10.64%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.06 - $1.79 $6,315 - $10,664	5,958 Added 15.81%	43,642 $52,000
Q1 2025 May 13, 2025	SELL	$1.26 - $3.49 $166,666 - $461,639	-132,275 Reduced 77.83%	37,684 $47,000
Q4 2024 Feb 14, 2025	BUY	$3.18 - $4.46 $266,951 - $374,403	83,947 Added 97.6%	169,959 $552,000
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $1,413 - $2,614	471 Added 0.55%	86,012 $282,000
Q2 2024 Aug 13, 2024	SELL	$3.31 - $18.51 $572,027 - $3.2 Million	-172,818 Reduced 66.89%	85,541 $363,000
Q1 2024 May 13, 2024	BUY	$9.77 - $21.47 $1.22 Million - $2.69 Million	125,348 Added 94.24%	258,359 $3.8 Million
Q4 2023 Feb 09, 2024	BUY	$4.48 - $10.11 $145,779 - $328,979	32,540 Added 32.39%	133,011 $1.28 Million
Q3 2023 Nov 09, 2023	SELL	$4.48 - $6.19 $22,341 - $30,869	-4,987 Reduced 4.73%	100,471 $468,000
Q2 2023 Aug 11, 2023	BUY	$4.62 - $7.54 $139,727 - $228,039	30,244 Added 40.21%	105,458 $564,000
Q1 2023 May 12, 2023	BUY	$4.82 - $7.24 $22,731 - $34,143	4,716 Added 6.69%	75,214 $539,000
Q4 2022 Feb 08, 2023	BUY	$3.34 - $6.98 $7,621 - $15,928	2,282 Added 3.35%	70,498 $473,000
Q3 2022 Nov 10, 2022	BUY	$3.01 - $5.22 $23,712 - $41,123	7,878 Added 13.06%	68,216 $236,000
Q2 2022 Aug 10, 2022	SELL	$2.25 - $9.99 $172,012 - $763,735	-76,450 Reduced 55.89%	60,338 $178,000
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $15,752 - $32,786	-1,940 Reduced 1.4%	136,788 $1.21 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $1.56 Million - $2.14 Million	97,898 Added 239.77%	138,728 $2.23 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $257,133 - $373,846	13,026 Added 46.85%	40,830 $855,000
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $623,592 - $1.08 Million	-30,434 Reduced 52.26%	27,804 $746,000
Q1 2021 May 12, 2021	BUY	$18.99 - $33.2 $1.08 Million - $1.89 Million	56,881 Added 4191.67%	58,238 $1.86 Million
Q4 2020 Feb 11, 2021	BUY	$19.41 - $26.0 $9,200 - $12,324	474 Added 53.68%	1,357 $31,000
Q3 2020 Nov 12, 2020	SELL	$24.69 - $31.6 $81,328 - $104,090	-3,294 Reduced 78.86%	883 $23,000
Q2 2020 Jul 31, 2020	SELL	$5.2 - $29.12 $32,505 - $182,029	-6,251 Reduced 59.94%	4,177 $116,000
Q1 2020 May 01, 2020	SELL	$4.28 - $12.11 $77,733 - $219,941	-18,162 Reduced 63.53%	10,428 $61,000
Q4 2019 Feb 14, 2020	SELL	$7.95 - $12.27 $553,145 - $853,722	-69,578 Reduced 70.88%	28,590 $311,000
Q3 2019 Nov 14, 2019	BUY	$12.44 - $17.48 $1.21 Million - $1.71 Million	97,648 Added 18778.46%	98,168 $1.25 Million
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $35,085 - $47,658	-2,418 Reduced 82.3%	520 $9,000
Q1 2019 May 14, 2019	SELL	$11.11 - $25.6 $1.02 Million - $2.35 Million	-91,698 Reduced 96.9%	2,938 $53,000
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $1.08 Million - $1.97 Million	91,796 Added 3232.25%	94,636 $1.2 Million
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $45,068 - $54,896	2,340 Added 468.0%	2,840 $61,000
Q2 2018 Aug 14, 2018	SELL	$19.78 - $24.67 $270,293 - $337,115	-13,665 Reduced 96.47%	500 $10,000
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $245,796 - $422,369	13,012 Added 1128.53%	14,165 $357,000
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $7,916 - $9,926	489 Added 73.64%	1,153 $22,000
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $2,545 - $3,106	164 Added 32.8%	664 $12,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,208 Reduced 70.73%	500 $9,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,708	1,708 $31,000

Others Institutions Holding MGNX

# of Institutions

119

Shares Held

52.3M

Call Options Held

55.3K

Put Options Held

35.9K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $107M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account